apolog delay initi read baxter result ere posit compani beat sale ep guidanc
came ahead street/our estim one might ask stock under-perform rel market
et share dow hile dow healthcar equip supply/ healthcar index
dow
call manag quantifi sale benefit across five six main product categori million
pt saw benefit higher sale renal replac therapi infus pump infus set mini-bag iv solut nutrit
gener inject use icu acceler suppli china pd product higher sale advanc surgeri ell
manag note expect continu see demand product manag provid guidanc
mani compani
 attribut under-perform bit cautiou commentari call near-term outlook
summar full note
manag expect sale grow deceler sequenti note exposur elect procedur
 advanc surgeri inhal anesthesia product hich ould partial off-set grow th busi advanc surgeri
inhal anesthesia also highest profit margin busi compani ill pressur margin
believ cautiou commentari appropri baxter busi expos level stock ahead
may clear
higher oper cost manag expect incur increment expens address pandem
includ cost includ measur protect employe safeti compens frontlin employe signific effort
boost product meet demand higher freight relat cost manag note take effort reduc discretionari
spend ould off-set higher cost ould drag margin y/i
oper cost seem like theyv cut well year there much room cut manag note sg
 ould see benefit reduc travel meet expens ould off-set increas technolog invest
expens along ith higher spend compens ith lost commiss base compens appropri ould
essenti keep employe base stabl recoveri also remain plan baxter need
spend innov top line grow th central long-term top line acceler plan
commentari interest expens also like higher y/i share repurchas program paus
view believ despit quarter come higher expect consensu estim could potenti prove high
given baxter commentari around maintain spend increment cost higher interest expens paus share repurchas
program prior compani result ep estim street year next note compani also
push investor day meet schedul later fall next year admittedli know fall bring
especi mani health expert discuss potenti second wave maintain equal weight rate
reach via bloomberg im kstew email plan revert back post call kristen
baxter medic necessari product extraordinari demand product includ prismax crrt product spectrum iq
iv set mini-bag parent nutrit iv drug use icu
manufactur oper modifi limit employe interact possibl ad perman
 ork ith fda bring oxiri filter set market eua
six gbu three segment contribut posit perform busi heighten demand given
slow dow demand elect slow dow advanc surgeri
sign partnership ith medaw privat cover
plan investor meet septemb due delay meet next year
reflect perform medic necessari portfolio
sale billion report constant currenc oper reflect underli strength busi
increas product pandem demand contribut approxim sale quarter
adjust ep ere ahead guidanc driven oper perform includ posit impact
partial off-set low er pension incom fx loss balanc sheet posit
constant currenc growth oper growth except advanc surgeri busi
sale geographi
america constant currenc oper basi
emea constant currenc oper basi
apac constant currenc oper basi
sale product categori
renal sale ere constant currenc driven high singl digit pd grow th global given china region travel
restrict acceler monthli pd suppli deliveri contribut hich off-set low er in-cent hd sale
medic deliveri sale ere constant currenc basi continu benefit strong execut spectrum
iq evo iq placement global estim increas demand iv solut minibag plu contribut
pharmaceut sale ere constant currenc strong grow th gener inject portfolio enhanc
demand pharmaceut use patient cyclo ou pharma compound contribut quarter grow th
 partial off-set low er sale anesthesia transderm scop benefit
nutrit sale ere constant currenc basi manag estim sale benefit given increas
util
advanc surgeri constant currenc oper acquisit seprafilm ad sale
perform first tw month increas demand hemostat sealant benefit competitor suppli declin
acut therapi sale ere grow th constant currenc surg demand renal therapi acut kidney
injuri earli studi show sever develop aki manag estim demand
ad grow th quarter
categori contract manufactur primari constant currenc basi
adjust margin y/i posit top line favor manufactur varianc
sg flat y/i continu priorit expens manag
 y/i report invest innov
op margin y/i
net interest y/i higher debt balanc
non-oper expens driven declin pension gain due transfer pension asset fx loss
vs outflow year ago strength balanc sheet sustain durabl
flow gener remain prioriti neg impact focus maintain liquid
cash/equival includ ltd issu euro access credit ell
busi develop remain import compon situat econom impact continu evolv focu ill
augment portfolio focus strateg suggest
suspend share repurchas program author remain
given high degre uncertainti guidanc provid updat
expect sale advanc slow er pace
signific declin advanc surgeri off-set grow th busi
expect incur increment expens address pandem cost includ measur protect employe safeti
compens frontlin employe signific effort boost product meet demand expect absorb freight relat
cost get product need
expect impact low er sale higher margin product advanc surgeri inhal anesethsia portfolio
chang plan spend
sg benefit reduc travel meet expens off-set increas technolog invest expens
along ith higher compens ith lost commiss base compens appropri
higher interest bond offer low er interest incom rate cut full year interest expens increas versu
 hatev take address critic patient need ell posit financi success
seem like bottom improv compani applic baxter see
challeng ell anticip one base case level rebound acceler thing keep mind
strong last year lot uncertainti keep mind ith evolv
oxiri think revenu opportun made europ heparin coat dont data
seem last longer filter anticoagul usual clog filter longer ork
collect data propos keep product market us crisi subsid good result outsid us
updat akhi prove point home therapi ideal cant comment rule moment
think right move govern baxter make invest ork ith partner
slow growth expect give guidanc hich signific level volatil impact
busi demand gave guidanc ith eek left signific beat guidanc top line
unpreced environ plan team lead david roman develop variou scenario plan
 ere increment benefit advanc surgeri ill meaning declin part deferr
surgeri didnt impact much ill atch resum april may ill affect
might capac constrain fluid dont constraint ith except minibag plu extra shift
put extra amount protect alloc next eek part constraint crrt made coupl
differ place orld place capac constraint see demand multipl time hat
produc futur ill area go grow go ork diversif site fluid around
globe drug use back-up dont make propofol us ou anoth one dexm outstrip capac
 ill make invest gallaxi technolog move forw ard
glimps april look like offer april in-lin ith expect predict largest
impact ith ould occur april may start see rebound june better
simpli one scenario look biggest advanc surgeri april may proceed line ith base
expect noth ild term commentari far april expect ith mani hospit close elect
sale forc product sale forc advanc surgeri give technic skill product line train cathet
insert global ebinar keep engag employe frontlin hospit across globe gave
employe increment incent
infus pump dynam bolu demand need pump patient need pump otherw ise ould
icu ramp product sigma spectrum approv canada new pump platform novum iq file
us file eua ell hospit strip resourc think convers today look demand
hospit manag inventori critic care hole integr suppli chain focu compani hospit
hard say point ant say ant make sure avail suppli meet patient need talk
challeng hurrican season least year pandem situat stabil ill carri extra inventori
critic product didnt show day inventori hand expect surg march ill
build inventori think hospit ill think inventori think hospit built inventori march think
consum manag think ill see stock pile hen demand surg eas think may
stock pile product govern may think differ
china see see normalci come back asia baxter busi slightli differ
europ america heavi periton dialysi busi china hich chronic diseas saw stock pile go
consum busi consist constant hospit go back surgeri go back
elsew asia ith except japan havent figur lockdow may delay australia
think possibl second ave think asia mostli home care chronic care busi
oper margin could y/i given increment spend talk sever impact term increment
spend ill drag dow margin prepar comment y/i margin grow th cant off-set increment
expens sg save like go happen baxter view cost essenti long-
term success businesshav custom employe compens employe ho
difficult situat ill drag oper margin y/i
incom tax tax rate busi mix favor saw benefit y/i dow nside due fa excess benefit
experienc last year incom offload pension plan result longer see pension incom
balanc sheet loss contribut y/i declin incom
periton dialysi new patient start saw healthi level new patient start noth differ think ill see pick
middl year depend cathet insert despit say elect
could see slow -dow pd due demand insert may issu short-term
revaclear impact around impact hat find plant produc record level prepar tow ard
end year theranova de novo go fda ill start convert ill see sw ap
progress kidney initi think invest build higher number soon
know outlook longer term dont see long term impact ahki see paus right
matter still front center hite hous ant still move forw ard matter time
comment outlook stock flow pre-buy
hospit ere anticip come us much consum manag believ vast major
sale advanc surgeri area like inhal anesthet extent delay curtain
 ill see impact second ave evolv long ave hospit react that hy guidanc
side ill atch see thing evolv hat ave impact point ill better posit could
stockpil occur nation level ill atch ell
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
